Literature DB >> 12603526

Longer survival in female than male with hepatocellular carcinoma.

Kazufumi Dohmen1, Hirohisa Shigematsu, Koji Irie, Hiromi Ishibashi.   

Abstract

AIM: There is a limited amount of data regarding the gender difference in the survival in cases of hepatocellular carcinoma (HCC). The aim of the present study was to investigate the difference in the survival between males and females with HCC and the possible factors affecting the gender difference of survival in HCC.
METHODS: Analyses were performed based on 704 consecutive patients with HCC observed for 12 years between January 1989 and December 2000 at the Internal Medicine Department, Saga Prefectural Hospital Koseikan, who were retrospectively enrolled in the study. The 1-, 3-, 5- and 7-year survivals and various factors at the detection of HCC were compared between 487 male and 217 female patients with HCC using the Kaplan-Meier method, Mantel-Cox test, chi squared test and Fisher's exact analysis.
RESULTS: There was a significant difference in survival between male and female patients with a 1-, 3-, 5- and 7-year survival estimate of 67.7, 40.6, 23.8 and 8.7%versus 73.5, 50.3, 26.3 and 15.4%, respectively (P-value: 0.0167). Of the clinical variables examined, the significant factors related to gender difference were found to be age, tumor size, the number of tumors, the presence of portal thrombosis and the type of follow-up. Of the patients with HCC lesions measuring 3 cm or less in the greatest dimension or those with solitary HCCs, however, there was no significant difference in survival between both sexes. The patients were divided into three categories: closely followed-up group (regular periodic follow-up with monthly alpha-fetoprotein measurements plus ultrasonography at least every 4 months); a non-closely followed-up group; and an incidental group (incidentally discovered due to related symptoms). The detection rates of HCC through the closely followed-up, non-closely followed-up and incidental groups were 19.3%, 46.2% and 34.5% in men and 28.1%, 46.5% and 25.4% in women, respectively, which reached a significant difference between both sexes (P-value: 0.0097).
CONCLUSION: The survival of female cases of HCC was longer than that of male cases. Disparities in the type of follow-up for women in comparison to men exist and may contribute to gender disparities in survival. Women with a high risk for HCC tended to be better cared for during the follow-up. To reduce gender disparities in survival, efforts should be directed at the earlier identification of HCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12603526     DOI: 10.1046/j.1440-1746.2003.02936.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  18 in total

1.  Predictors of liver transplant eligibility for patients with hepatocellular carcinoma in a safety net hospital.

Authors:  Amit G Singal; Vincent Chan; Yonas Getachew; Richard Guerrero; Joan S Reisch; Jennifer A Cuthbert
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

2.  Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer.

Authors:  Yu-Lin Sun; Jian-Qiang Cai; Fang Liu; Xin-Yu Bi; Lan-Ping Zhou; Xiao-Hang Zhao
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

3.  Gender-based outcomes differences in unresectable hepatocellular carcinoma.

Authors:  Shama C Buch; Venkateswarlu Kondragunta; Robert A Branch; Brian I Carr
Journal:  Hepatol Int       Date:  2007-12-15       Impact factor: 6.047

4.  SNPs in the promoter region of the osteopontin gene as a possible host factor for sex difference in hepatocellular carcinoma development in patients with HCV.

Authors:  Kazuhiro Hamaoka; Sumiko Nagoshi; Kayoko Sugawara; Kayoko Naiki; Yoshihito Uchida; Mie Inao; Nobuaki Nakayama; Kenji Fujiwara; Satoshi Mochida
Journal:  Hepatol Int       Date:  2012-10-06       Impact factor: 6.047

5.  Differential Proteomic Analysis of Gender-dependent Hepatic Tumorigenesis in Hras12V Transgenic Mice.

Authors:  Zhuona Rong; Tingting Fan; Huiling Li; Juan Li; Kangwei Wang; Xinxin Wang; Jianyi Dong; Jun Chen; Fujin Wang; Jingyu Wang; Aiguo Wang
Journal:  Mol Cell Proteomics       Date:  2017-05-16       Impact factor: 5.911

6.  Long noncoding RNA FTX inhibits hepatocellular carcinoma proliferation and metastasis by binding MCM2 and miR-374a.

Authors:  F Liu; J-H Yuan; J-F Huang; F Yang; T-T Wang; J-Z Ma; L Zhang; C-C Zhou; F Wang; J Yu; W-P Zhou; S-H Sun
Journal:  Oncogene       Date:  2016-04-11       Impact factor: 9.867

7.  MicroRNA expression, survival, and response to interferon in liver cancer.

Authors:  Junfang Ji; Jiong Shi; Anuradha Budhu; Zhipeng Yu; Marshonna Forgues; Stephanie Roessler; Stefan Ambs; Yidong Chen; Paul S Meltzer; Carlo M Croce; Lun-Xiu Qin; Kwan Man; Chung-Mau Lo; Joyce Lee; Irene O L Ng; Jia Fan; Zhao-You Tang; Hui-Chuan Sun; Xin Wei Wang
Journal:  N Engl J Med       Date:  2009-10-08       Impact factor: 91.245

8.  Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma.

Authors:  Pisit Tangkijvanich; Varocha Mahachai; Pongspeera Suwangool; Yong Poovorawan
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

9.  United States women receive more curative treatment for hepatocellular carcinoma than men.

Authors:  Stephanie Cauble; Ali Abbas; Luis Balart; Lydia Bazzano; Sabeen Medvedev; Nathan Shores
Journal:  Dig Dis Sci       Date:  2013-06-29       Impact factor: 3.199

10.  Clinical Features and Overall Survival of Females with Hepatocellular Carcinoma: A Retrospective Study and Review of the Literature in the Association of Southeast Asian Nations.

Authors:  Sarita Ratana-Amornpin; Ratha-Korn Vilaichone; Muhammad Miftahussurur; Natsuda Aumpan; Kittipong Kaewkarnjanarat; Pongjarat Nun-Anan; Soonthorn Chonprasertsuk; Sith Siramolpiwat; Patommatat Bhanthumkomol; Bubpha Pornthisarn; Tomohisa Uchida; Varocha Mahachai
Journal:  Int J Womens Health       Date:  2021-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.